Neurotensin
A gut-brain peptide that modulates dopamine transmission, pain sensitivity, and fat absorption — linking metabolic health to schizophrenia and addiction research.
A 13-amino-acid peptide found in the brain and GI tract that modulates dopaminergic neurotransmission, produces non-opioid analgesia, promotes fat absorption, and is a research target for schizophrenia and addiction.
Mechanism of action
Binds NTS1 (high-affinity, Gq-coupled — mediates analgesia and dopamine modulation), NTS2 (mediates analgesia), and NTS3/sortilin. In the VTA, NT enhances dopamine neuron firing. In the gut, promotes fat absorption.
Primary uses
- Endogenous modulation of dopaminergic neurotransmission
- Non-opioid analgesia research
- Fat absorption and GI motility regulation
- Schizophrenia research
- Cancer targeting (NT-PRRT)
Typical dosing
Not used therapeutically. Plasma NT rises 2-3-fold after a fat-rich meal.
Regulatory status
Not approved as a drug. NTS1 receptor agonists are in preclinical development for analgesia and antipsychotic effects. NT-PRRT is in clinical trials for neurotensin receptor-positive cancers.
References
- [pubmed] Carraway R, Leeman SE. "The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami." J Biol Chem. 1973;248(19):6854-6861.
- [review] Boules M, et al. "Diverse roles of neurotensin agonists in the central nervous system." Front Endocrinol. 2013;4:36.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.